State
of New
York
|
1-10113
|
11-0853640
|
||
(State
of Other Jurisdiction
of Incorporation) |
(Commission
File Number)
|
(I.R.S.
Employer
Identification Number) |
o |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
o |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d- 2(b))
|
o |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR
240.13e- 4(c))
|
Exhibit Number |
Description
|
10.1 |
Omnibus
Amendment and Consent effective as of May 24, 2006 between the Registrant
and various lenders.
|
99.1 |
Press
Release dated May 24, 2006 Announcing Receipt of Bridge Funding and
the
Extension of the Maturity Date of Outstanding Bridge
Loans
|
ACURA PHARMACEUTICALS, INC. | ||
|
|
|
By: | /s/ Peter A. Clemens | |
Peter A. Clemens |
||
Senior Vice President & Chief Financial Officer |
Exhibit Number |
Description
|
10.1 |
Omnibus
Amendment and Consent effective as of May 24, 2006 between the
Registrant
and various lenders.
|
99.1 |
Press
Release dated May 24, 2006 Announcing Receipt of Bridge Funding
and the
Extension of the Maturity Date of Outstanding Bridge
Loans
|